Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABLE: Abraxane + Pembrolizumab in Advanced Urothelial Cancer
NCT03240016Phase 2Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Feb 2018
- Primary completion
- Jun 2023
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nab-paclitaxel in urothelial carcinoma (UC), sponsored by University of Michigan Rogel Cancer Center. Primary endpoint: Overall Response Rate at 24 months. Started Feb 2018; status: completed.
02
Drugs
nab-paclitaxel
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03240016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03240016.